HARBIN, China, July 24, 2012 /PRNewswire-Asia/ -- China Botanic
Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the
"Company"), a developer, manufacturer and distributor of botanical
products, bio-pharmaceuticals and Traditional Chinese Medicines
("TCM") in China, today announced
that the Company was recently granted a new patent (Patent No: ZL
201010119871.7) on its advanced proprietary Schisandra Lignin
Extraction Method.
The new patent grant followed a two year process of
comprehensive evaluation conducted by the State Intellectual
Property Office of the People's Republic
of China ("SIPO"). SIPO completed a preliminary review of
China Botanic's patent application in May
2010. On July 4, 2012, the
Company was granted the patent on its Schisandra Lignin extraction
method and Schisandra-based products with market exclusivity for a
period of 18 years. In addition to the new patent on its Schisandra
Lignin extraction method, the Company also currently owns a patent
on the extraction of effective ingredients of Siberian Ginseng and
its preparation and application.
Research in China suggests that
Schisandra is a wild plant with significant medical and health
benefits. Schisandra has been found to prevent liver damage and is
an effective sedative for treating insomnia and central nervous
system depression. Additionally, research indicates Lignin
compounds are a good source of powerful anti-oxidants with
promising benefits in fighting major conditions, including HIV,
cancer and high blood pressure. China Botanic's proprietary
Schisandra lignin extraction method enables the Company to obtain
higher purity of lignin and remove impurities from the plant,
resulting in extract with over 50% lignin, which may substantially
enhance the efficacy of medicines produced from these
compounds.
"We are pleased to receive the patent on our proprietary
Schisandra Lignin Extraction Method, which positively reflects on
our research capabilities to develop new medicines," said Mr.
Shaoming Li, Chairman and CEO of
Renhuang Pharmaceuticals, Inc. "We at China Botanic are committed
to enhancing our research and development potential and strive
towards developing products that benefit our consumers and society.
We believe securing patents on our products and technology
strengthens our ability to market them effectively and deliver long
term shareholder value. We will continue to execute on our
intellectual property strategy and expand our patent
portfolio."
About China Botanic Pharmaceutical Inc.
China Botanic Pharmaceutical Inc. is engaged in the research,
development, manufacturing, and distribution of botanical products,
bio-pharmaceutical products, and traditional Chinese medicines
("TCM"), in the People's Republic of
China. All of the Company's products are produced at its
three GMP-certified production facilities in Ah City, Dongfanghong
and Qingyang. The Company distributes its botanical anti-depression
and nerve-regulation products, biopharmaceutical products, and
botanical antibiotic and OTC TCMs through its network of over 3,000
distributors and over 70 sales centers across 24 provinces in
China. For more information,
please visit www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may
include forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are based upon management's beliefs, assumptions and expectations
of the Company's future operations and financial performance,
taking into account the information currently available to
management. These statements are not statements of historical fact.
Forward-looking statements involve risks and uncertainties, some of
which are not currently known that may cause actual results,
performance or financial condition to be materially different from
the expectations of future results, performance or financial
condition expressed or implied in any forward-looking statements.
These forward-looking statements are based on current plans and
expectations and are subject to a number of uncertainties
including, but not limited to, the Company's ability to manage
expansion of its operations effectively, and other factors detailed
in the Company's annual report on Form 10-K and other filings with
the Securities and Exchange Commission. The Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented herein.
Company Contact:
China Botanic Pharmaceutical Inc.
Ms. Portia Tan, IR Contact
Tel: 86-451-8260-2162
Email: ir@renhuang.com
CCG Investor Relations:
Mr. Mark Collinson, Partner
Phone: +1-310-954-1343 (Los
Angeles)
Email:mark.collinson@ccgir.com
Website: www.ccgirasia.com
SOURCE China Botanic Pharmaceutical Inc.
